All
Results: 63445-63456 of 70454

Denodo Named a Leader in the 2023 Gartner® Magic Quadrant™ for Data Integration Tools for Four Consecutive Years

Imlifidase demonstrated positive safety, tolerability, and early efficacy outcomes in 15-HMedIdeS-09 phase 2 trial in Guillain-Barré Syndrome (GBS)



